CRISPR-Cas9高通量文库筛选技术在胶质瘤中的应用进展  

Progress in Application of CRISPR-Cas9 High-throughput Library Screening Technology in Glioma

作　　者：濮蓓 张旭[1] 熊晓星[1] 简志宏[1] 曾智[2] PU Bei;ZHANG Xu;XIONG Xiaoxing;JIAN Zhihong;ZENG Zhi(Department of Neurosurgery,Renmin Hospital of Wuhan University,Wuhan 430060,China;Department of Pathology,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院神经外科,武汉430060 [2]武汉大学人民医院病理科,武汉430060

出　　处：《医学综述》2023年第13期2568-2573,共6页Medical Recapitulate

摘　　要：胶质瘤是最常见的神经系统肿瘤,其治疗以手术切除、术后辅助放化疗为主,但效果不理想,预后较差。成簇间隔规律短回文重复序列(CRISPR)-CRISPR相关蛋白9(Cas9)高通量文库筛选技术以合成致死治疗策略为基础,通过CRISPR-Cas9技术对胶质瘤细胞进行基因编辑,将单向导RNA转入细胞中,在全基因组范围内干扰基因功能并筛选目的表型,以获得一系列与肿瘤发生发展机制及治疗相关的靶基因。目前,CRISPR-Cas9高通量文库筛选技术在胶质瘤中被广泛研究,已在细胞模型、动物模型等模型中获得了一系列与胶质瘤增殖、药物敏感性及耐药相关的靶基因,这可为后续临床胶质瘤的个体化靶向治疗提供新的指导方向,以得到更好的临床治疗效果。Glioma is the most common nervous system tumor,and its treatment is mainly surgical resection and postoperative adjuvant chemotherapy,but the effect is not ideal and the prognosis is poor.Clustered regularly interspaced short palindromic repeats(CRISPR)-CRISPR associated protein 9(Cas9)high-throughput library screening technology is based on synthetic lethal therapeutic strategies,and glioma cells are genetically edited by CRISPR-Cas9 technology to transfer single guide RNA into cells,interfere with gene function genome-wide and screen target phenotypes to obtain a series of target genes related to tumor development mechanism and treatment.Currently,CRISPR-Cas9 high-throughput library screening technology has been widely studied in glioma,and a series of target genes related to glioma proliferation,drug sensitivity and drug resistance have been obtained in cellular models and animal models,which can provide a new direction for the subsequent individualized targeted treatment of glioma in the clinic to obtain better clinical treatment results.

关 键 词：胶质瘤 成簇间隔规律短回文重复序列-CRISPR相关蛋白9 合成致死 高通量文库筛选 

分 类 号：R739.41[医药卫生—肿瘤]